Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTISLEGA: Tislelizumab + FLOT in Resectable Esophagogastric Adenocarcinoma
NCT07059299Phase 1Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in esophagogastric junction adenocarcinoma (GEJA), gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Feasibility rate at 8 months. Started Dec 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
esophagogastric junction adenocarcinoma (GEJA)gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07059299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059299.